Dernières nouvelles pour ATAI Life Sciences (NASDAQ:ATAI) Stock

ATAI Life Sciences

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.

<a href="https://www.marijuanamoment.net/massachusetts-psychiatric-society-endorses-bill-to-decriminalize-psilocybin-possession/" title="https://www.marijuanamoment.net/massachusetts-psychiatric-society-endorses-bill-to-decriminalize-psilocybin-possession/">https://www.marijuanamoment.net/massachusetts-psychiatric-society-endorses-bill-to-decriminalize-psilocybin-possession/</a>

Biotech

News

General

ATAI

CMPS

CYBN

DRUG

ENVB

MNMD

'Massachusetts Psychiatric Society Endorses Bill To Decriminalize Psilocybin Possession' - Marijuana Moment

WIIM

ATAI stock has given up its prior gain. ATAI Life Sciences shares were trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a price target of $14.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Ladenburg Thalmann initiated coverage on Comstock Inc. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LODE#AMEX">LODE</a>) with a Buy rating and announced a price target of $12. Comstock shares closed at $3.45 on Monday. <a href="https://www.benzinga.com/quote/LODE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer analyst Jay Olson initiated coverage on Atai Life Sciences N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) with an Outperform rating and announced a price target of $14. ATAI Life Sciences shares closed at $3.33 on Monday. <a href="https://www.benzinga.com/quote/ATAI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt analyst Kevin Garrigan initiated coverage on D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) with a Buy rating and announced a price target of $30. D-Wave Quantum shares closed at $18.35 on Monday. <a href="https://www.benzinga.com/quote/QBTS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt analyst Kevin Garrigan initiated coverage on IonQ, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) with a Buy rating and announced a price target of $70. IonQ shares closed at $42.34 on Monday. <a href="https://www.benzinga.com/quote/IONQ/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying ATAI stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/ATAI/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29090736/image-453-1024x585.png" alt="" class="wp-image-1005180" style="width:592px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29090736/image-453-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29090736/image-453-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29090736/image-453-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29090736/image-453.png 1122w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="http://Sbenzinga.com/markets/equities/25/07/46679452/boeing-procter-gamble-and-3-stocks-to-watch-heading-into-tuesday">Boeing, Procter &amp; Gamble And 3 Stocks To Watch Heading Into Tuesday</a></li>
</ul>
Photo via Shutterstock

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

IONQ

LODE

QBTS

This Atai Life Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

ATAI Life Sciences shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a price target of $14.

Oppenheimer analyst Jay Olson initiates coverage on ATAI Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) with a Outperform rating and announces Price Target of $14.

Price Target

Oppenheimer Initiates Coverage On ATAI Life Sciences with Outperform Rating, Announces Price Target of $14

Canaccord Genuity analyst Sumant Kulkarni maintains ATAI Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) with a Buy and lowers the price target from $12 to $11.

Canaccord Genuity Maintains Buy on ATAI Life Sciences, Lowers Price Target to $11

Amid a surge in research targeting cognitive disorders, the pharmaceutical industry is witnessing a wave of pivotal trial results that could reshape schizophrenia treatment paradigms. As biotech firms race to develop innovative therapies, Recognify Life Sciences steps into the spotlight with new findings <a href="https://www.benzinga.com/general/biotech">from its latest clinical trial.</a>
Recognify Life Sciences announced data from a randomized, double-blind, placebo-controlled Phase 2b trial evaluating inidascamine (formerly RL-007) in patients with cognitive impairment <a href="https://www.benzinga.com/general/biotech" target="_blank" rel="noreferrer noopener">associated with schizophrenia (CIAS)</a>. Recognify is a strategic investment of ATAI Life Sciences N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>).
<ul class="wp-block-list">
<li>ATAI stock is tumbling in today&#8217;s session. <a href="https://www.benzinga.com/quote/ATAI" target="_blank" rel="noreferrer noopener">Check the price action here.</a></li>
</ul>
The trial did not meet its primary endpoint of improvement on the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MCCB) neurocognitive composite score at Week 6.
Also Read: <a target="_blank" href="https://www.benzinga.com/cannabis/25/07/46194289/atai-life-sciences-and-merger-partner-set-up-psychedelic-depression-therapy-with-encouraging-late-stage-data" rel="noreferrer noopener">Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data</a>
The company on Monday said the inidascamine demonstrated a modest but consistent numerical improvement across the overall MCCB neurocognitive composite and multiple individual subdomains, including Symbol Coding, Speed of Processing, and Verbal Learning<a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46643996/recognify-life-sciences-provides-update-on-phase-2b-trial-of-inidascamine-in-patients-with-cogniti" rel="noreferrer noopener"> (immediate recall)</a>.
Directionally positive effects were also observed on the Virtual Reality Functional Capacity Assessment Tool (VRFCAT), a real-world functional <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41915173/abbvies-schizophrenia-failure-disappoints-but-analysts-show-confidence-in-immunology-portfolio" rel="noreferrer noopener">cognitive capacity measure</a>.
Inidascamine was well-tolerated, with a favorable safety profile consistent with previous studies.
No evidence of sedation, weight gain, or extrapyramidal symptoms was observed, which are side effects commonly associated with schizophrenia treatments.
The study enrolled 242 patients.
Recognify plans to present additional results from the study at upcoming scientific meetings and will continue to evaluate strategic options for inidascamine based on the totality of data.
In November 2024, AbbVie&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41884798/abbvies-emraclidine-for-schizophrenia-surprisingly-disappoints-analyst-says-pipeline-is-underappreciated" rel="noreferrer noopener">two Phase 2 trials</a>.
The studies did not meet their primary endpoint of showing a statistically significant improvement in the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score compared to the placebo group at week 6.
In September 2024, the FDA approved Bristol Myers Squibb &amp; Co.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for <a href="https://www.benzinga.com/pressreleases/24/09/b41059140/u-s-food-and-drug-administration-approves-bristol-myers-squibbs-cobenfy-xanomeline-and-trospium-ch" target="_blank" rel="noreferrer noopener">schizophrenia in adults</a>.
Cobenfy represents the first new class of medicine in several decades and introduces a fundamentally new approach to treating schizophrenia by selectively targeting M1&nbsp;and M4&nbsp;receptors in the brain without blocking D2&nbsp;receptors.
ATAI Price Action: ATAI Life Sciences shares were down 9.38% at $3.23 at the time of publication on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/07/46657092/can-american-airlines-navigate-financial-turbulence-ahead" target="_blank" rel="noreferrer noopener">Can American Airlines Navigate Financial Turbulence Ahead?</a></li>
</ul>
Photo: Shutterstock

Health Care

Movers

ABBV

Why Is ATAI Life Sciences Stock Trading Lower On Monday?

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.3% on Monday.
Shares of ATAI Life Sciences NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) fell sharply in pre-market trading after the company announced the Phase 2b trial of Inidascamine in patients with cognitive impairment associated with schizophrenia did not meet<a href="https://www.benzinga.com/quote/ATAI"> its primary endpoint.</a>
ATAI Life Sciences shares dipped 9.3% to $3.23 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Fusion Fuel Green PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) declined 9.2% to $6.29 in pre-market trading. Fusion Fuel Green shares jumped 47% on Friday after the company announced its subsidiary has confirmed several new projects.</li>
<li>Revvity Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NASDAQ">RVTY</a>) fell 7.4% to $96.00 in pre-market trading as the company lowered its FY2025 earnings guidance.</li>
<li>KB Financial Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KB#NYSE">KB</a>) shares declined 5.1% to $81.50 in pre-market trading after declining 5% on Friday.</li>
<li>Rapport Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPP#NASDAQ">RAPP</a>) fell 4.9% to $15.27 in pre-market trading after falling 3% on Friday.</li>
<li>Metsera Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) declined 4.9% to $38.50 in pre-market trading.</li>
<li>Volcon Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLCN#NASDAQ">VLCN</a>) fell 4.6% to $12.79 in pre-market trading.</li>
<li>Shinhan Financial Group Co Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHG#NYSE">SHG</a>) fell 4.6% to $48.59 in pre-market trading. On Friday, Shinhan Financial Group posted second-quarter earnings of $2.19 per share on sales of $2.048 billion.</li>
<li>Cantor Equity Partners I Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEPO#NASDAQ">CEPO</a>) tumbled 4.3% to $11.35 in pre-market trading.</li>
<li>Quantumscape Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) fell 3.6% to $11.54 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46655271/top-3-health-care-stocks-that-may-explode-in-july">Top 3 Health Care Stocks That May Explode In July</a></li>
</ul>
Photo via Shutterstock

CEPO

HTOO

MTSR

RAPP

RVTY

VLCN

ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session

CELC: 133% &#x7C; <a href="https://www.benzinga.com/node/46655428">Celcuity Released Topline Results From PIK3CA Wild-Type Cohort Of Phase 3 VIKTORIA-1 Trial Of Gedatolisib Plus Fulvestrant With And Without Palbociclib Versus Fulvestrant In Advanced Breast Cancer</a>
&nbsp;
TSLA: 2% &#x7C; <a href="https://www.benzinga.com/node/46651922">Elon Musk Confirms Tesla As the Mystery Big-Tech That Signed $16.5 Billion Chip Contract With Samsung: 'I Will Walk The Line Personally' To Boost Progress (UPDATED)</a>
&nbsp;
ATAI: -20% &#x7C; <a href="https://www.benzinga.com/node/46644203">ATAI Life Sciences shares are trading lower after the company announced the Phase 2b trial of Inidascamine in patients with cognitive impairment associated with schizophrenia did not meet its primary endpoint.</a>

CELC

TSLA

Market-Moving News for July 28th

U.S. stock futures rose on Monday after ending higher on Friday. Futures of major benchmark indices were higher.
President Donald Trump announced a 15% tariff <a href="https://www.benzinga.com/news/politics/25/07/46650830/donald-trump-announces-15-tariff-trade-agreement-with-eu-ending-months-of-trade-uncertainty">trade deal with the European Union</a> (EU) on Sunday, putting an end to several months of trade uncertainty with the U.S.'s biggest trade partner. 
The tariff rate is a significant drop from the 30% Trump threatened on July 12 and the 20% he proposed on April 2. Trump stated that the EU will not impose a tariff on U.S. imports, describing the deal as "satisfactory to both sides."
Investors will assess a slew of macro and micro indicators this week, as the Federal Reserve&#8217;s interest rate decision, along with the second-quarter GDP data, will be released on Wednesday.
Additionally, earnings from companies including Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), and Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) are expected this week.
Meanwhile, the 10-year Treasury bond yielded 4.37% and the two-year bond was at 3.91%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing a 96.99% likelihood of the Federal Reserve keeping the current interest rates unchanged in its July meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.16%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.27%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.47%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.53%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were higher in premarket on Friday. The SPY was up 0.28% at $638.91, while the QQQ advanced 0.50% to $569.22, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
On Friday, industrials, materials, and consumer discretionary stocks led the gains among S&amp;P 500 sectors, while energy and communication services stocks ended the session lower, bucking the overall positive trend.
U.S. stocks settled higher, with the S&amp;P 500 marking its 14th record close this year, fueled by optimism over corporate earnings and global trade talk progress, which bolstered risk assets.
All three major indices saw weekly gains, with the 30-stock Dow rising approximately 1.3%, the broad S&amp;P 500 climbing about 1.5%, and the tech-heavy Nasdaq adding 1%.
Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) reported better-than-expected second-quarter financial results. Conversely, Carter&#8217;s Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRI#NYSE">CRI</a>) shares dropped around 20% after the company missed second-quarter adjusted EPS estimates, suspended its fiscal 2025 guidance, and cited tariff impacts.
On the economic data front, U.S. durable goods orders fell 9.3% month-over-month to $311.84 billion in June, following a revised 16.5% gain in May.
The Dow Jones index ended 208 points or 0.47% higher at 44,901.92, whereas the S&amp;P 500 index rose 0.40% to 6,388.64. Nasdaq Composite advanced 0.24% to 21,108.32, and the small-cap gauge, Russell 2000, gained 0.40% to end at 2,261.07.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.24%</td>
<td>21,108.32</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.40%</td>
<td>6,388.64</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.47%</td>
<td>44,901.92</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.40%</td>
<td>2,261.07</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
The Director and Senior Investment Strategist at Charles Schwab &amp; Co., Kevin Gordon, highlighted that the week ahead was crucial with important market-moving data scheduled to be released during this period.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Here&#39;s what we have next week: Apple earnings Amazon earnings Microsoft earnings Meta earnings FOMC rate decision JOLTS Conference Board consumer confidence PCE inflation ISM Manufacturing UMich June jobs report August 1 tariff deadline Other than that, should be pretty quiet
&mdash; Kevin Gordon (@KevRGordon) <a href="https://twitter.com/KevRGordon/status/1948107799613059455?ref_src=twsrc%5Etfw">July 23, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
According to Ed Yardeni of Yardeni Research, &#8220;Naturally, the main event will be the Federal Open Market Committee's widely expected decision (Wed) to leave the federal funds rate unchanged. We are among those expecting no change.&#8221;
However, he expects that Fed Chair Jerome Powell&#8216;s press conference (Wed) will be relatively dovish, raising the odds of a September rate cut. &#8220;Nevertheless, we remain in the none-and-done camp in 2025 for now,&#8221; Yardeni added.
However, senior economist Mohamed El Erian noted that Trump&#8217;s Fed visit last week underscored &#8220;differing interpretations.&#8221;
According to him, some viewed it as a &#8220;truce,&#8221; citing the President&#8217;s pledge not to fire Chair Powell and his expectation that the Chair would &#8220;do the right thing&#8221; by cutting interest rates.
Whereas others saw the visit as an escalation, aligning with Steve Bannon&#8217;s &#8220;flood the zone&#8221; strategy. &#8220;They point to the awkward televised exchange between the President and Chair Powell regarding the renovation&#8217;s cost as evidence of continued and clear friction,&#8221; he added.
&#8220;This week promises to be an exceptionally busy one, packed with notable policy decisions, major economic data releases, and systemically important corporate earnings – all set against the backdrop of seasonally thinner market liquidity,&#8221; Erian added.
Meanwhile, Jamie Cox, the managing partner for Harris Financial Group spoke about the U.S. deal with EU.
&#8220;When Japan broke down and made a deal the EU had little choice. The biggest piece in the trade deal puzzle still remains, and the Chinese are unlikely to be as willing to fold. The next big durable theme in markets is security, and the EU deal only accelerates it,&#8221; he said.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures</a> 
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on this week:
<ul class="wp-block-list">
<li>No data is scheduled to be released on Monday.</li>
<li>On Tuesday, June&#8217;s advanced U.S. trade balance in goods, retail inventories, and wholesale inventories data will be announced by 8:30 a.m. ET.</li>
<li>May&#8217;s S&amp;P Case-Shiller home price index for 20 cities will be out by 9:00 a.m., July&#8217;s consumer confidence data, and June&#8217;s job openings data will be released by 10:00 a.m. ET.</li>
<li>On Wednesday, July ADP employment will be out by 8:15 a.m. and the second quarter&#8217;s GDP data will be released by 8:30 a.m. ET.</li>
<li>June&#8217;s pending home sales data will be released by 10:00 a.m. and the FOMC interest rate decision will be bout by 2:00 p.m., with the Federal Reserve Chair Powell addressing a press conference at 2:30 p.m. ET.</li>
<li>On Thursday, the initial jobless claims data for the week ended July 26, the second quarter&#8217;s Employment Cost Index data, June personal income, spending, and the headline and core PCE Index data will all be released at 8:30 a.m. ET.</li>
<li>July&#8217;s Chicago Business Barometer (PMI) will be out by 9:45 a.m. ET.</li>
<li>On Friday, July&#8217;s U.S. employment report, unemployment rate, and hourly wages data will be announced by 8:30 a.m. ET.</li>
<li>July&#8217;s S&amp;P final U.S. manufacturing PMI will be released at 9:45 a.m., whereas July&#8217;s ISM manufacturing, construction spending, and consumer sentiment will be announced by 10:00 a.m. ET.</li>
<li>July&#8217;s auto sales data will also be released on Friday.</li>
</ul>
Stocks In Focus:
<ul class="wp-block-list">
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) stock rose 1.72% in premarket on Monday after it confirmed a massive $16.5 billion chip manufacturing deal with Samsung Electronics.</li>
<li>Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) was up 1.44% after the U.S. Army on Friday awarded a $100 million, 11-month Next-Generation Command and Control prototype contract, part of a broader $3 billion Department of Defense request for fiscal 2026.</li>
<li>UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) was up 1.30% after it released a statement responding to the Department of Justice after a review of the media reports about investigations into specific aspects of its involvement in the Medicare program.</li>
<li>Anghami Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGH#NASDAQ">ANGH</a>) zoomed 38.65% the company appointed James Cooke, a senior executive from Warner Bros Discovery Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>), to its Board of Directors. Additionally, its shareholders also approved a 1-for-10 reverse stock split.</li>
<li>Mill City Ventures III Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCVT#NASDAQ">MCVT</a>) surged 91.68% following a recent halt in trading due to a circuit breaker. On Friday, the stock was halted after a 211.3% increase, leading to a temporary suspension in trading.</li>
<li>ATAI Life Sciences NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) dropped 16.81% after disclosing that the Phase 2b trial of Inidascamine in patients with cognitive impairment associated with schizophrenia did not meet its primary endpoint.</li>
<li>Enterprise Products Partners LP. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>) was 0.95% higher as analysts expect it to report earnings of 65 cents per share on revenue of $15.04 billion before the opening bell.</li>
<li>Nucor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) advanced 1.09% as it is expected to report earnings after the closing bell. Analysts estimate earnings of $2.65 per share on revenue of $8.51 billion.</li>
<li>Waste Management Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) added 0.25% as analysts expect it to report earnings of $1.89 per share on revenue of $6.37 billion after the closing bell.</li>
<li>Whirlpool Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHR#NYSE">WHR</a>) rose 0.76% as it is expected to report earnings after the closing bell. Analysts estimate earnings of $1.78 per share on revenue of $3.90 billion.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 0.95% to hover around $65.78 per barrel.
Gold Spot US Dollar rose 0.01% to hover around $3,337.38 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index spot was higher by 0.51% at the 98.1430 level.
Asian markets mostly advanced on Monday, except Japan's Nikkei 225 and India's S&amp;P BSE Sensex indices. South Korea's Kospi, Hong Kong's Hang Seng, China&#8217;s CSI 300, and Australia's ASX 200 indices rose. European markets were mostly higher in early trade.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46652124/bitcoin-ethereum-dogecoin-climb-on-trump-eu-trade-pact-analyst-says-this-risk-off-signal-could-be-critical-as-btc-drives-entire-crypto-market">Bitcoin, Ethereum, Dogecoin Climb On Trump-EU Trade Pact — Analyst Says This &#8216;Risk-Off&#8217; Signal Could Be Critical As BTC Drives Entire Crypto Market</a></li>
</ul>
Photo courtesy: godongphoto / Shutterstock.com

Equities

AAPL

AMZN

ANGH

MCVT

MSFT

PLTR

US Stocks Likely To Open Higher As US-EU Ink Trade Deal: Tesla, Palantir, UnitedHealth In Focus

Shares of Celcuity Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) rose sharply in pre-market trading after the company announced it will disclose the topline results of the PIK3CA Wild-Type Cohort from the Phase 3 <a href="https://www.benzinga.com/quote/CELC">VIKTORIA-1 trial</a>.
Celcuity jumped 12.6% to $15.50 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>CEA Industries Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VAPE#NASDAQ">VAPE</a>) shares gained 804.5% to $80.28 in pre-market trading after gaining 4% on Friday.</li>
<li>Mill City Ventures III Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCVT#NASDAQ">MCVT</a>) rose 79.8% to $10.60 in pre-market trading after jumping 219% on Friday.</li>
<li>Majestic Ideal Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MJID#NASDAQ">MJID</a>) shares jumped 44.2% to $2.61 in pre-market trading after falling 5% on Friday.</li>
<li>Anghami Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGH#NASDAQ">ANGH</a>) climbed 38.3% to $0.64 in pre-market trading. On July 23, the company appointed James Cooke, a senior executive from Warner Bros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>), to its Board of Directors—bringing industry expertise and potentially strengthening strategic ties. Additionally, to boost compliance and potentially enhance investor appeal, Anghami shareholders also approved a 1-for-10 reverse stock split.</li>
<li>22nd Century Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) gained 34.6% to $4.13 in pre-market trading after gaining 4% on Friday. 22nd Century Group recently announced several tobacco brands are partnering with the organization to expand their availability and awareness.</li>
<li>Nvni Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) surged 25.7% to $0.53 in pre-market trading.</li>
<li>Aeye Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIDR#NASDAQ">LIDR</a>) surged 19.5% to $5.30 in pre-market trading. AEye shares jumped 52% on Friday after the company announced it filed an amendment to update its maximum number of the company&#8217;s common shares up to an aggregate of $23.728 million placement shares.</li>
<li>INmune Bio Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NYSE">INMB</a>) gained 19.5% to $3.24 in pre-market trading.</li>
<li>Hotel101 Global Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBNB#NASDAQ">HBNB</a>) rose 15.2% to $2.84 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Sidus Space Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) dipped 47.5% to $1.06 in pre-market trading after the company announced the pricing of public offering.</li>
<li>180 Life Sciences Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) declined 15% to $2.55 in pre-market trading after gaining over 40% on Friday.</li>
<li>Eightco Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCTO#NASDAQ">OCTO</a>) dipped 12.9% to $2.15 in pre-market trading after jumping 72% on Friday.</li>
<li>Psyence Biomedical Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares tumbled 11.7% to $10.16 in pre-market trading after gaining 15% on Friday.</li>
<li>Zooz Power Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZOOZ#NASDAQ">ZOOZ</a>) declined 10.7% to $3.27 in pre-market trading after gaining 29% on Friday. Maxim Group analyst Tate Sullivan, on July 24, downgraded Zooz Power from Buy to Hold.</li>
<li>ATAI Life Sciences NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) fell 9.3% to $3.23 in pre-market trading after the company announced the Phase 2b trial of Inidascamine in patients with cognitive impairment associated with schizophrenia did not meet its primary endpoint.</li>
<li>Fusion Fuel Green PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) fell 9.2% to $6.29 in pre-market trading. Fusion Fuel Green shares jumped 47% on Friday after the company announced its subsidiary has confirmed several new projects.</li>
<li>Next Technology Holding Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) fell 6.2% to $2.10 in pre-market trading after declining more than 5% on Friday.</li>
<li>KB Financial Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KB#NYSE">KB</a>) shares fell 5.1% to $81.50 in pre-market trading after declining 5% on Friday.</li>
<li>Cantor Equity Partners I Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEPO#NASDAQ">CEPO</a>) fell 4.3% to $11.35 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46653283/sp-500-notches-5th-consecutive-record-close-following-strong-earnings-investor-sentiment-edges-lower-but-fear-index-remains-in-greed-zone">S&amp;P 500 Notches 5th Consecutive Record Close Following Strong Earnings: Investor Sentiment Edges Lower, But Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>
Photo via Shutterstock

ATNF

HBNB

INMB

LIDR

MJID

NVNI

Next Technology Holding Inc. - Ordinary Shares

NXTT

OCTO

SIDU

VAPE

XXII

ZOOZ

Why Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
<ul class="wp-block-list">
<li>Wall Street expects Enterprise Products Partners L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>) to report quarterly earnings at 65 cents per share on revenue of $15.04 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Enterprise Products Partners shares fell 0.8% to close at $31.55 on Friday.</li>
<li>Analysts are expecting Nucor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) to have earned $2.65 per share on revenue of $8.51 billion after the closing bell. Nucor shares gained 3.1% to close at $145.83 on Friday.</li>
<li>ATAI Life Sciences NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) disclosed that the Phase 2b trial of Inidascamine in patients with cognitive impairment associated with schizophrenia did not meet its primary endpoint. ATAI Life Sciences shares fell 4.6% to close at $3.57 on Friday.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul class="wp-block-list">
<li>After the markets close, Waste Management Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) is projected to post quarterly earnings at $1.89 per share on $6.37 billion. Waste Management shares fell 0.4% to close at $229.67 on Friday.</li>
<li>Analysts expect Whirlpool Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHR#NYSE">WHR</a>) to post quarterly earnings at $1.78 per share on revenue of $3.90 billion after the closing bell. Whirlpool shares rose 1.1% to close at $99.74 on Friday.</li>
</ul>
Check This Out: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46628925/top-2-materials-stocks-that-may-fall-off-a-cliff-this-month">Top 2 Materials Stocks That May Fall Off A Cliff This Month</a></li>
</ul>

Nucor, Waste Management And 3 Stocks To Watch Heading Into Monday

ATAI Life Sciences shares are trading lower after the company announced the Phase 2b trial of Inidascamine in patients with cognitive impairment associated with schizophrenia did not meet its primary endpoint.

Initial results demonstrate numerical improvement of cognitive and functional measures with inidascamine across both active treatment arms compared to placebo, but did not meet statistical significance on the primary endpoint
<ul>
<li>Inidascamine continues to exhibit a favorable safety and tolerability profile</li>
<li>Full data set, including secondary endpoints and subgroup analyses will be forthcoming
	&nbsp;</li>
</ul>
SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on developing treatments for cognitive impairment, today announced that its randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating inidascamine (formerly RL-007) in patients with cognitive impairment associated with schizophrenia (CIAS) did not meet its primary endpoint.
While the study did not achieve statistical significance on its primary endpoint of improvement on the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MCCB) neurocognitive composite score at Week 6, inidascamine demonstrated a modest but consistent numerical improvement across the overall MCCB neurocognitive composite and multiple individual subdomains, including Symbol Coding, Speed of Processing and Verbal Learning (immediate recall). Directionally positive effects were also observed on the Virtual Reality Functional Capacity Assessment Tool (VRFCAT), a measure of real-world functional cognitive capacity.
Inidascamine was well-tolerated, with a favorable safety profile consistent with previous studies. Importantly, no evidence of sedation, weight gain, or extrapyramidal symptoms was observed, which are side effects commonly associated with treatments used in people living with schizophrenia.
The randomized, placebo-controlled, double-blind, Phase 2b clinical study enrolled 242 patients across the United States and Europe (NCT05686239). The trial evaluated the efficacy, safety, and tolerability of two doses of inidascamine versus placebo over a six-week treatment period. A comprehensive analysis of remaining secondary and exploratory endpoints, including subgroup analyses, is ongoing to determine whether there are identifiable responder populations or mechanistic insights that may guide future development.
Recognify plans to present additional results from the study at upcoming scientific meetings and will continue to evaluate strategic options for inidascamine based on the totality of data.
&nbsp;

ATAI Life Sciences' Strategic Investment Co Recognify Life Sciences Announces Its Randomized, Double-Blind, Placebo-Controlled Phase 2b Clinical Trial Evaluating Inidascamine In Patients With CIAS Did Not Meet Its Primary Endpoint

GHRS

Shares of psychedelic companies are trading higher following a report suggesting California Governor Newsom said he is "all in" on expanding access to psychedelics for therapeutic use.

<a href="https://www.marijuanamoment.net/california-governor-hes-all-in-on-psychedelic-therapy-access-but-worries-about-capitalists-commercializing-it/" title="https://www.marijuanamoment.net/california-governor-hes-all-in-on-psychedelic-therapy-access-but-worries-about-capitalists-commercializing-it/">https://www.marijuanamoment.net/california-governor-hes-all-in-on-psychedelic-therapy-access-but-worries-about-capitalists-commercializing-it/</a>

'California Governor He's 'All In' On Psychedelic Therapy Access, But Worries About Capitalists Commercializing It' - Marijuana Moment

Canaccord Genuity analyst Sumant Kulkarni maintains ATAI Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) with a Buy and raises the price target from $11 to $12.

Canaccord Genuity Maintains Buy on ATAI Life Sciences, Raises Price Target to $12

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling over 150 points on Tuesday.
The Dow traded up 1.03% to 44,549.24 while the NASDAQ declined 0.76% to 20,215.20. The S&amp;P 500 also fell, dropping, 0.12% to 6,197.21.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46191543/how-to-earn-500-a-month-from-unifirst-stock-ahead-of-q3-earnings">How To Earn $500 A Month From UniFirst Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Health care shares jumped by 1.5% on Tuesday.
In trading on Tuesday, information technology stocks fell by 1%.
Top Headline
The ISM manufacturing PMI rose to 49 in June versus 48.5 in the previous month, compared to market estimates of 48.8.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Atai Life Sciences N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) shares shot up 19% to $2.6048 after the company announced it raised $50 million via a private placement.</li>
<li>Shares of Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) got a boost, surging 116% to $0.8596 after the company initiated its pre-packaged restructuring process.</li>
<li>ClearOne, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRO#NASDAQ">CLRO</a>) shares were also up, gaining 106% to $12.08. The company announced it will issue a one-time special stock dividend on July 18.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Oragenics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#NYSE">OGEN</a>) shares dropped 57% to $1.6394 after the company announced a $20 million public offering of preferred stock and warrants.</li>
<li>Shares of Sonim Technologies, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONM#NASDAQ">SONM</a>) were down 47% to $0.6500 after the company announced the pricing of a $5.55 million offering of 7,400,000 shares at $0.75 per share.</li>
<li>Aeva Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NASDAQ">AEVA</a>) was down, falling 27% to $27.77.</li>
</ul>
Commodities In commodity news, oil traded up 0.7% to $65.57 while gold traded up 1.4% at $3,353.90.
Silver traded up 0.8% to $36.475 on Tuesday, while copper rose 0.5% to $5.1065.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.21%, while Spain's IBEX 35 Index fell 0.03%. London's FTSE 100 rose 0.28%, Germany's DAX 40 declined 0.99% and France's CAC 40 slipped 0.04% during the session.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei dipping 1.24%, China's Shanghai Composite gaining 0.39% and India's BSE Sensex gaining 0.11%.
Economics
<ul class="wp-block-list">
<li>The S&amp;P Global manufacturing PMI climbed to 52.9 in June compared to 52 in the previous month, and initial market estimates of 51.</li>
<li>The number of job quits increased by 78,000 to 3.293 million in May compared to the revised 3.215 million in the previous month.</li>
<li>The number of job openings climbed by 374,000 to 7.769 million in May.</li>
<li>The ISM manufacturing PMI rose to 49 in June versus 48.5 in the previous month, compared to market estimates of 48.8.</li>
<li>The RealClearMarkets/TIPP Economic Optimism Index fell to 48.6 in July compared to 49.2 in the previous month.</li>
<li>U.S. construction spending declined by 0.3% month-over-month to an annual rate of $2,138 billion in May.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46192054/cramer-backs-this-mining-giant-after-1-6b-bet">Cramer Backs This Mining Giant After $1.6B Bet</a> </li>
</ul>
Photo via Shutterstock

Earnings

Eurozone

Commodities

Intraday Update

AEVA

CLRO

OGEN

SONM

WOLF

Nasdaq Dips 150 Points; US ISM Manufacturing PMI Rises In June

U.S. stocks were mixed, with the Dow Jones index gaining over 250 points on Tuesday.
Shares of Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) rose sharply during Tuesday's session after the company announced alignment with the U.S. Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor (rexlemestrocel-L) for ischemic heart failure with reduced ejection <a href="https://www.benzinga.com/quote/MESO">fraction (HFrEF) and inflammation</a>.
Mesoblast shares jumped 11.8% to $12.18 on Tuesday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Atai Life Sciences N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) shares jumped 30.3% to $2.8549 after the company announced it raised $50 million via a private placement.</li>
<li>McEwen Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUX#NYSE">MUX</a>) gained 13.6% to $10.91.</li>
<li>Bloomin&#8217; Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMN#NASDAQ">BLMN</a>) gained 11.9% to $9.63.</li>
<li>Citius Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) gained 11% to $4.8300.</li>
<li>Melco Resorts &amp; Entertainment Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLCO#NASDAQ">MLCO</a>) rose 10.8% to $8.02 after JP Morgan upgraded the stock from Neutral to Overweight and raised its price target from $7.2 to $9.5.</li>
<li>Studio City International Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSC#NYSE">MSC</a>) gained 10.7% to $3.5159.</li>
<li>IREN Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) gained 9.3% to $15.93. IREN named Anthony Lewis as Chief Capital Officer to lead capital markets strategy.</li>
<li>Wynn Resorts, Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) rose 9.1% to $102.24. Shares of casino stocks trading higher after Macau June casino revenue reportedly rose.</li>
<li>Las Vegas Sands Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>) gained 7.4% to $46.74.</li>
<li>Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) rose 7% to $49.79.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46190223/top-3-tech-stocks-that-could-lead-to-your-biggest-gains-in-july">Top 3 Tech Stocks That Could Lead To Your Biggest Gains In July</a> </li>
</ul>
Photo via Shutterstock

BLMN

CTOR

IREN

MESO

Melco Resorts & Entertainment Limited - American Depositary Shares

MLCO

WYNN

Mesoblast, Atai Life Sciences, Melco Resorts & Entertainment And Other Big Stocks Moving Higher On Tuesday

Atai Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) and Beckley Psytech Limited jointly announced topline results from the eight-week, quadruple-masked, dose-finding core stage of the Phase 2b trial of a single dose of BPL-003 (intranasal mebufotenin (5-MeO-DMT) benzoate) in patients with <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">treatment-resistant depression </a>(TRD).
The study achieved its primary endpoint as well as all key secondary endpoints.
In June, the companies announced their plan to combine in an all-share transaction, subject to the pre-agreed <a href="https://www.benzinga.com/pressreleases/25/06/g45716633/atai-life-sciences-and-beckley-psytech-to-combine-creating-a-global-leader-in-psychedelic-mental-h">Phase 2b success criteria</a> for BPL-003 (mebufotenin benzoate).
The transaction is expected to close in the second half of 2025. 
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/cannabis/25/05/45601096/ex-govt-foe-joins-trump-rfk-jr-s-hhs-to-lead-psychedelics-policy-what-it-means-for-investors" rel="noreferrer noopener">Ex-Gov&#8217;t Foe Joins Trump, RFK Jr.&#8217;s HHS To Lead Psychedelics Policy: What It Means For Investors</a>
<h2 class="wp-block-heading">Key Efficacy Findings:</h2>
At Day 29, a single 12 mg dose of BPL-003 demonstrated a statistically significant reduction in depressive symptoms, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS), with a mean decrease of 11.1 points from baseline compared to a 5.8 point reduction in the 0.3 mg <a href="https://www.benzinga.com/pressreleases/25/07/g46189490/atai-life-sciences-and-beckley-psytech-announce-positive-topline-results-from-the-phase-2b-study-o" target="_blank" rel="noreferrer noopener">comparator group (p = 0.0038)</a>.
For the key secondary efficacy endpoints, a single 8 mg dose of BPL-003 also showed significant improvement at Day 29, with a mean MADRS score reduction of 12.1 points (p = 0.0025 for change vs. the 0.3 mg control). The 8mg and 12mg of BPL-003 showed statistically significant improvements in MADRS scores as early as one day after dosing, with these effects generally maintained through Week 8.
The 8 mg and 12 mg doses of BPL-003 demonstrated equivalent efficacy, suggesting the 8 mg dose may be sufficient to achieve therapeutic benefit from a single dose.
The difference in MADRS scores between the 8 mg and 12 mg doses versus the 0.3 mg dose were statistically significant in both active arms from as early as Day 2, with mean MADRS reductions from baseline of 8.8 points in the 8 mg group and 8.9 points in the 12 mg group observed at that timepoint, compared to a reduction from baseline of 3.9 points in the 0.3 mg group.
These mean reductions from baseline increased to 11.1 points in the 8 mg group and 10.8 points in the 12 mg group at Day 8.
A durable effect was also observed for both higher doses, with the 8 mg group showing a mean reduction of 10.8 points from baseline at Day 57 and the 12 mg group showing a mean reduction of 10.2 points from baseline compared with the 0.3 mg group (5.2 point reduction).
<h2 class="wp-block-heading">Key Safety Findings:</h2>
Safety and efficacy results from this study support the selection of the 8 mg dose of BPL-003 for advancement into Phase 3 clinical studies.
More than 99% of treatment-emergent adverse events (TEAEs) were mild or moderate; there were no drug-related serious adverse events (SAEs).
Dose-related increases in administration site discomfort, nausea, headache, blood pressure, and anxiety suggest that the 8mg dose was better tolerated than the 12mg dose.
No participants in the 8 mg or 12 mg arms had any instance of treatment-emergent suicidal intent or behaviour, indicating no suicide-related safety signal observed to date.
Follow-up in the study&#8217;s eight-week open-label extension (OLE) stage is ongoing.
The OLE study evaluates the safety and efficacy of a second 12 mg BPL-003 administered to patients eight weeks after dosing in the core study. Data from the OLE study is expected in the third quarter of 2025 and will provide additional insights into the safety and tolerability of repeat dosing, as well as the durability of BPL-003&#8217;s antidepressant effect.
Concurrently, on Tuesday, Atai Life Sciences announced the private placement of 18.3 million shares with a nominal value of €0.10 (approximately $0.11) and pre-funded warrants to purchase 4.6 million shares, with approximately <a href="https://www.benzinga.com/pressreleases/25/07/g46189588/atai-life-sciences-announces-50-million-private-placement-financing" target="_blank" rel="noreferrer noopener">$50 million in gross proceeds</a>.
Price Action: ATAI stock was up 28.3% at $2.81 during the premarket session at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/legal/25/07/46193030/johnson-johnsons-drug-discount-plan-gets-thrown-out-in-court" target="_blank" rel="noreferrer noopener">Johnson &amp; Johnson&#8217;s Drug Discount Plan Gets Thrown Out In Court</a></li>
</ul>
Photo: Shutterstock

Cannabis

Psychedelics

Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data

Press Releases

atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech's Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression

atai Life Sciences to Participate in Upcoming Investor Conferences

Financing

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, STRM, ATAI, STR on Behalf of Shareholders

ATAI Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Atai Life Sciences N.V. is Fair to Shareholders

Legal

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

atai Life Sciences Announces $50 Million Private Placement Financing

Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

BPMC

ICAD

LNSR

SAGE

STRM

Oppenheimer

Canaccord Genuity

HC Wainwright & Co.

Maxim Group

EF Hutton

Screenshot 2024-05-21 at 6.46.56 PM

SILO

FTRP

Revolutionizing Mental Healthcare With The Rise Of Ketamine And Psychedelic Therapies

Comments

ATAI Life Sciences

Actualités

Dernières nouvelles pour ATAI Life Sciences (NASDAQ:ATAI) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL